(Solid Tumors) FDA Grants Accelerated Approval for Jemperli in dMMR Advanced Solid Tumors
(Solid Tumors) FDA Grants Accelerated Approval for Jemperli in dMMR Advanced Solid Tumors
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
(Solid Tumors) FDA Grants Accelerated Approval for Jemperli in dMMR Advanced Solid Tumors
- August 24, 2021
- Read time: 1 minute
On August 17, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Jemperli for patients with recurrent or advanced solid tumors with mismatch repair deficiency (dMMR) who have progressed during or after treatment and have no satisfactory alternative therapeutic options. Additionally, the FDA approved Ventana MMR RxDx Panel as a companion diagnostic for dMMR solid tumor patients using Jemperli.
The efficacy of Jemperli was evaluated in the GARNET (NCT02715284) clinical trial, a non-randomized, multicenter, open-label, multi-cohort study. The trial included 209 patients with dMMR recurrent or advanced solid tumors who experienced disease progression after systemic therapy and had no satisfactory alternative treatment.
The primary endpoint objective response rate was 41.6%, with complete response in 9.1% and partial response in 32.5%. The median duration of response was 34.7 months, with 95.4% of patients achieving response duration of 6 months or longer.
The most common adverse events (≥20%) in dMMR solid tumor patients were fatigue, weakness, anemia, diarrhea, and nausea. The most common Grade 3 or 4 adverse events (≥2%) were anemia, fatigue, weakness, elevated transaminases, sepsis, and acute kidney injury. Additionally, immune-related adverse effects of Jemperli include pneumonitis, colitis, hepatitis, endocrine disorders, nephritis, and skin toxicity.
The recommended dose of Jemperli is 500mg every 3 weeks for cycles 1 through 4, then 1,000mg every 6 weeks starting 3 weeks after the fourth dose, administered intravenously over approximately 30 minutes.
-
Clinical Trial Medications
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase II Clinical Trial Results. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4